Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Biomaterials. 2018 May 26;176:71–83. doi: 10.1016/j.biomaterials.2018.05.041

Fig. 3. THR enhances AAV8 transduction in vivo in a dose-dependent manner, especially in the brain.

Fig. 3

(A) On days 3 and 7 after the administration of AAV8 or different doses of complexes, the images were taken for luminescence analysis. (B) The average luciferase signal for the liver and whole body (excluding the liver) in the mice treated with different doses of THR was calculated. (C) The gene copy numbers in liver, brain, and spleen were determined separately. The data of each group represents the average and SD from five mice. *** p < 0.001, ** p < 0.01, and *p < 0.05 compared to control mice with AAV8 treatment only. The “ns” indicates no significant difference (p> 0.05).